Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
NL-OMON56021Phase 2Recruiting
- Sponsor
- Amgen
- Start
- Jun 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of blinatumomab in B lymphoblastic leukemia/lymphoma (B-ALL/LBL) (6 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities and safety in dose escalation, Remission endpoint in dose expansion and phase 2 relapsed/refractory cohorts and 2 more. Started Jun 2023; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B lymphoblastic leukemia/lymphoma (B-ALL/LBL)
Beyond the preview
Go deeper on NL-OMON56021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56021.